FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to a method of treating or preventing pain. Method of treating or preventing pain in a human subject in need thereof, where the person has Fabry disease and where the pain is selected from neuropathic pain, gastrointestinal pain and peripheral neuropathy, comprising administering to a subject an effective amount of a compound of formula (I)
or a pharmaceutically acceptable salt or prodrug thereof, where R1 is selected from hydrogen, halogen, cyano, nitro, hydroxy, thio, amino, C1-6-alkyl, C2-6-alkenyl, C1-6-alkyloxy, C2-6-alkenyloxy and C2-6-alkynyloxy, where said alkyl, alkenyl, alkynyl, alkyloxy, alkenyloxy or alkynyloxy is optionally substituted with one or more groups selected from halogen, cyano, nitro, hydroxy, thio or amino; R2 and R3 are independently selected from C1-3-alkyl, optionally substituted with one or more halogens, or R2 and R3 together form a cyclopropyl or cyclobutyl group, optionally substituted with one or more halogens; R4, R5 and R6 are each independently selected from hydrogen, halogen, nitro, hydroxy, thio, amino, C1-6-alkyl and C1-6-alkyloxy, where said alkyl or alkyloxy is optionally substituted with one or more in groups, selected from halogen, hydroxy, cyano and C1-6-alkyloxy; and A is 5- or 6-membered aryl or heteroaryl group, optionally substituted with 1, 2 or 3 groups, independently selected from halogen, hydroxy, thio, amino, nitro, C1-6-alkoxy or C1-6-alkyl.
EFFECT: use of the invention provides the treatment or prevention of pain, including neuropathic pain, gastrointestinal pain and peripheral neuropathy, in a human subject in need thereof, where the person has Fabry disease.
15 cl, 19 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS OF TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | 2020 |
|
RU2824599C2 |
QUINAZOLIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | 2020 |
|
RU2797606C1 |
GLUCOSYLCERAMIDE-SYNTHASE INHIBITORS | 2012 |
|
RU2645675C2 |
ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2020 |
|
RU2824528C2 |
TETRASUBSTITUTED ALKENE COMPOUNDS AND USE THEREOF | 2016 |
|
RU2733741C2 |
SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | 2015 |
|
RU2695649C2 |
POLYMORPHIC FORM OF DIARYL MACROCYCLE | 2016 |
|
RU2765181C2 |
INTEGRATED STRESS PATHWAY PRODRUG MODULATORS | 2019 |
|
RU2824500C2 |
AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS | 2018 |
|
RU2768149C2 |
OXAZOLIDINONE COMPOUNDS AND METHODS OF THEIR APPLICATION AS ANTIBACTERIAL AGENTS | 2016 |
|
RU2794494C2 |
Authors
Dates
2024-11-05—Published
2020-02-03—Filed